Published in AIDS Weekly, May 11th, 1998
Earlier recommendations issued by a panel of experts convened by the National Institutes of Health did not include Roche's saquinavir in its initial formulation (hard-gel capsules, trade name Invirase). But recently updated recommendations include the hard-gel version of the drug, trade name Fortovase, as well as Merck's indinavir (Crixivan), Abbott's ritonavir (Norvir), and Agouron's nelfinavir (Viracept).
And the new recommendations contain even more good news for Roche.
Based on new data (see AIDS Weekly Plus, March 30,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.